Healthy
Conditions
Brief summary
Study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of single rising oral doses of BI 10773 to healthy male subjects.
Interventions
DRUGBI 10773 single rising dose
DRUGPlacebo
Sponsors
Boehringer Ingelheim
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
MALE
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy males according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs ((blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), clinical laboratory tests 2. Age ≥ 18 and Age ≤ 50 years 3. BMI ≥ 18.5 and BMI ≤ 29.9 kg/m2 (Body Mass Index) 4. Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation
Exclusion criteria
1. Any finding of the medical examination including ((blood pressure (BP), pulse rate (PR), 12-lead electrocardiogram (ECG)) deviating from normal and of clinical relevance 2. Any evidence of a clinically relevant concomitant disease 3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders 4. Surgery of the gastrointestinal tract (except appendectomy) 5. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders 6. History of relevant orthostatic hypotension, fainting spells or blackouts. 7. Chronic or relevant acute infections 8. History of relevant allergy/hypersensitivity (including allergy to drug or its excipients) 9. Intake of drugs with a long half-life (\> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial 10. Use of drugs which might reasonably influence the results of the trial or that prolong the QT/QTc interval based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial 11. Participation in another trial with an investigational drug within two months prior to administration or during the trial 12. Smoker (\> 10 cigarettes or \> 3 cigars or \> 3 pipes/day) 13. Inability to refrain from smoking on trial days 14. Alcohol abuse (more than 60 g/day) 15. Drug abuse 16. Blood donation (more than 100 mL within four weeks prior to administration or during the trial) 17. Excessive physical activities (within one week prior to administration or during the trial) 18. Any laboratory value outside the reference range that is of clinical relevance 19. Inability to comply with the dietary regimen of trial site 20. A marked baseline prolongation of QT/QTc interval (e.g. repeated demonstration of a QTc interval \>450 ms); 21. A history of additional risk factors for torsade de pointes (e.g. heart failure, hypokalemia, family history of Long QT Syndrome);
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patients with adverse events | up to 33 days |
| Number of patients with clinically significant changes in vital signs | up to 12 days |
| Assessment of tolerability by investigator on a 4-point scale | up to day 4 |
| Number of patients with clinically significant changes in 12-lead electrocardiogram (ECG) | up to 12 days |
| Number of patients with abnormal findings in physical examination | up to 12 days |
| Number of patients with abnormal changes in laboratory parameters | up to 12 days |
Secondary
| Measure | Time frame |
|---|---|
| t1/2 (terminal half-life of the analyte in plasma) | up to 72 hours after drug administration |
| MRTpo (mean residence time of the analyte in the body after po administration) | up to 72 hours after drug administration |
| CL/F (total clearance of the analyte in the plasma after extravascular administration) | up to 72 hours after drug administration |
| Cmax (maximum concentration of the analyte in plasma) | up to 72 hours after drug administration |
| Ae t1-t2 (amount of analyte that is eliminated in urine from the time point t1 to time point t2) | up to 72 hours after drug administration |
| fe t1-t2 (fraction of analyte eliminated in urine from time point t1 to time point t2) | up to 72 hours after drug administration |
| CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2) | up to 72 hours after drug administration |
| Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose) | up to 72 hours after drug administration |
| tmax (time from dosing to maximum concentration) | up to 72 hours after drug administration |
| AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) | up to 72 hours after drug administration |
| %AUCtz-∞ (the percentage of the AUC0-∞ that is obtained by extrapolation) | up to 72 hours after drug administration |
| AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point) | up to 72 hours after drug administration |
| λz (terminal rate constant in plasma) | up to 72 hours after drug administration |
Outcome results
None listed